$3.97
+0.03
(+0.76%)▲
Insights on Chromadex Corp
Revenue is up for the last 2 quarters, 19.49M → 21.19M (in $), with an average increase of 8.0% per quarter
Netprofit is up for the last 3 quarters, -2.19M → 114.0K (in $), with an average increase of 534.9% per quarter
1.13%
Downside
Day's Volatility :6.02%
Upside
4.94%
68.51%
Downside
52 Weeks Volatility :73.12%
Upside
14.62%
Period | Chromadex Corp | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 175.52% | -0.5% | 0.0% |
6 Months | 203.08% | 5.9% | 0.0% |
1 Year | 173.61% | 3.1% | -1.9% |
3 Years | -52.98% | 14.2% | -21.8% |
Market Capitalization | 296.0M |
Book Value | $0.38 |
Earnings Per Share (EPS) | -0.07 |
PEG Ratio | 0.0 |
Wall Street Target Price | 6.47 |
Profit Margin | -5.91% |
Operating Margin TTM | -0.79% |
Return On Assets TTM | -6.42% |
Return On Equity TTM | -17.29% |
Revenue TTM | 83.6M |
Revenue Per Share TTM | 1.11 |
Quarterly Revenue Growth YOY | 1.0% |
Gross Profit TTM | 42.8M |
EBITDA | -4.6M |
Diluted Eps TTM | -0.07 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.01 |
EPS Estimate Next Year | 0.05 |
EPS Estimate Current Quarter | -0.03 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Upside of 62.97%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 31.6M | ↑ 48.84% |
Net Income | -33.3M | ↑ 192.82% |
Net Profit Margin | -105.57% | ↓ 51.91% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 46.3M | ↑ 46.69% |
Net Income | -31.5M | ↓ 5.54% |
Net Profit Margin | -67.99% | ↑ 37.58% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 59.3M | ↑ 28.01% |
Net Income | -18.5M | ↓ 41.27% |
Net Profit Margin | -31.19% | ↑ 36.8% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 67.4M | ↑ 13.82% |
Net Income | -25.6M | ↑ 38.27% |
Net Profit Margin | -37.89% | ↓ 6.7% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 72.1M | ↑ 6.82% |
Net Income | -14.4M | ↓ 43.46% |
Net Profit Margin | -20.05% | ↑ 17.84% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 83.6M | ↑ 15.99% |
Net Income | -4.9M | ↓ 65.82% |
Net Profit Margin | -5.91% | ↑ 14.14% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 17.1M | ↑ 1.98% |
Net Income | 1.1M | ↓ 117.09% |
Net Profit Margin | 6.42% | ↑ 44.71% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 21.0M | ↑ 23.05% |
Net Income | 673.0K | ↓ 38.54% |
Net Profit Margin | 3.21% | ↓ 3.21% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 22.6M | ↑ 7.43% |
Net Income | -1.3M | ↓ 297.62% |
Net Profit Margin | -5.9% | ↓ 9.11% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 20.3M | ↓ 9.9% |
Net Income | -2.2M | ↑ 64.74% |
Net Profit Margin | -10.78% | ↓ 4.88% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 19.5M | ↓ 4.07% |
Net Income | -959.0K | ↓ 56.23% |
Net Profit Margin | -4.92% | ↑ 5.86% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 21.2M | ↑ 8.73% |
Net Income | 114.0K | ↓ 111.89% |
Net Profit Margin | 0.54% | ↑ 5.46% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 42.2M | ↓ 32.67% |
Total Liabilities | 15.1M | ↑ 69.34% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 40.2M | ↓ 4.7% |
Total Liabilities | 19.8M | ↑ 31.54% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 38.4M | ↓ 4.69% |
Total Liabilities | 21.9M | ↑ 10.77% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 57.8M | ↑ 50.79% |
Total Liabilities | 26.1M | ↑ 19.05% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 54.1M | ↓ 6.54% |
Total Liabilities | 25.4M | ↓ 2.79% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 55.0M | ↑ 1.68% |
Total Liabilities | 26.5M | ↑ 4.42% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 45.7M | ↓ 2.03% |
Total Liabilities | 24.6M | ↓ 4.62% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 54.1M | ↑ 18.38% |
Total Liabilities | 25.4M | ↑ 3.02% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 53.8M | ↓ 0.53% |
Total Liabilities | 25.8M | ↑ 1.44% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 53.2M | ↓ 1.11% |
Total Liabilities | 26.0M | ↑ 1.05% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 53.5M | ↑ 0.59% |
Total Liabilities | 26.2M | ↑ 0.59% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 55.0M | ↑ 2.77% |
Total Liabilities | 26.5M | ↑ 1.27% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -20.9M | ↑ 113.26% |
Investing Cash Flow | -1.8M | ↓ 138.57% |
Financing Cash Flow | -90.0K | ↓ 100.18% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -20.4M | ↓ 2.24% |
Investing Cash Flow | -249.0K | ↓ 85.97% |
Financing Cash Flow | 16.9M | ↓ 18860.0% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -10.6M | ↓ 48.14% |
Investing Cash Flow | -165.0K | ↓ 33.73% |
Financing Cash Flow | 8.7M | ↓ 48.77% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -24.2M | ↑ 127.95% |
Investing Cash Flow | -409.0K | ↑ 147.88% |
Financing Cash Flow | 36.1M | ↑ 317.27% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -15.1M | ↓ 37.52% |
Investing Cash Flow | -334.0K | ↓ 18.34% |
Financing Cash Flow | 7.7M | ↓ 78.79% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -3.7M | ↓ 2.4% |
Investing Cash Flow | -52.0K | ↓ 38.82% |
Financing Cash Flow | -18.0K | ↑ 350.0% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -328.0K | ↓ 91.23% |
Investing Cash Flow | -172.0K | ↑ 230.77% |
Financing Cash Flow | 7.7M | ↓ 42761.11% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 2.8M | ↓ 951.22% |
Investing Cash Flow | -91.0K | ↓ 47.09% |
Financing Cash Flow | -1000.0 | ↓ 100.01% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 3.3M | ↑ 17.48% |
Investing Cash Flow | -5.0K | ↓ 94.51% |
Financing Cash Flow | -10.0K | ↑ 900.0% |
Sell
Neutral
Buy
Chromadex Corp is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Chromadex Corp | 31.77% | 203.08% | 173.61% | -52.98% | -52.98% |
Moderna, Inc. | -0.45% | 20.22% | -27.91% | -35.9% | 341.66% |
Regeneron Pharmaceuticals, Inc. | -6.85% | 6.85% | 9.08% | 78.94% | 160.71% |
Novo Nordisk A/s | -7.1% | 22.03% | 44.33% | 239.61% | 408.97% |
Vertex Pharmaceuticals Incorporated | -4.18% | 5.53% | 20.27% | 79.84% | 136.07% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Chromadex Corp | NA | NA | 0.0 | -0.01 | -0.17 | -0.06 | NA | 0.38 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.21 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.84 | 25.84 | 1.46 | 45.15 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.75 | 46.75 | 2.4 | 3.36 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.57 | 28.57 | 0.53 | 16.72 | 0.23 | 0.13 | NA | 68.22 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Chromadex Corp | Buy | $296.0M | -52.98% | NA | -5.91% |
Moderna, Inc. | Buy | $40.3B | 341.66% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.6B | 160.71% | 25.84 | 30.14% |
Novo Nordisk A/s | Buy | $559.8B | 408.97% | 46.75 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $102.7B | 136.07% | 28.57 | 36.68% |
Vanguard Group Inc
Tieton Capital Management, LLC
ICONIQ Capital, LLC
BlackRock Inc
Geode Capital Management, LLC
Renaissance Technologies Corp
Chromadex Corp’s price-to-earnings ratio stands at None
Read Morechromadex corp. is an integrated, global nutraceutical company devoted to improving the way people age. chromadex scientists partner with leading universities and research institutions worldwide to uncover the full potential of nad and identify and develop novel, science-based ingredients including pteropure® pterostilbene; purenergy®, a caffeine-pteropure® co-crystal; anthorigin™, anthocyanins and niagen® nicotinamide riboside - sold directly to consumers as the supplement, tru niagen®. tru niagen® is helping the world age better®. for more, visit www.chromadex.com like us on facebook here: https://www.facebook.com/chromadex or follow us on twitter @chromadex chromadex® is publicly-traded company (nasdaq:cdxc).
Organization | Chromadex Corp |
Employees | 106 |
CEO | Mr. Frank Louis Jaksch Jr. |
Industry | Process Industries |